U.S. FDA extends review of Exelixis' cancer drug

The ‌U.S. Food and Drug Administration has extended the review of ​Exelixis' experimental colorectal ​cancer drug combination by three ⁠months, the company said ​in a filing on ​Friday.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。